Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: Report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review

Edward P. Balaban, Mateel Graham, Steve Perkins, Richard G. Sheehan, Eugene P. Frenkel, Michael Ross, Joan Bull, Brian Pruitt, Phillip Periman, Chris Ruud, James Luce

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) modulation with either folinic acid (FA) or methotrexate (MTX) has improved 5-FU's potential cytoreductivity. We combined MTX and FA with 5-FU to further augment 5-FU's cytoreductivity. Patients (n = 34) with advanced colorectal carcinoma were first given intravenous MTX (escalated from 30 mg/m2 to 70 mg/m2). FA (100 mg/m2) was infused 17-24 hr later, followed by 5-FU (600 mg/m2). Oral rescue doses of FA were begun 24 hr after MTX. Patients were treated every 2 weeks. No previously treated patient (n = 6) responded. Eight of the remaining 28 (29% (95% confidence interval, 15-47% patients achieved a PR. Median survival was 9.3 months. Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29% These results, in addition to a literature review, reveal that the manipulation of 5-FU by two modulating agents does not improve the response rate seen with single-agent modulation.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalCancer Investigation
Volume12
Issue number1
DOIs
StatePublished - 1994

Fingerprint

Leucovorin
Methotrexate
Fluorouracil
Colorectal Neoplasms
Therapeutics
Confidence Intervals
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma : Report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. / Balaban, Edward P.; Graham, Mateel; Perkins, Steve; Sheehan, Richard G.; Frenkel, Eugene P.; Ross, Michael; Bull, Joan; Pruitt, Brian; Periman, Phillip; Ruud, Chris; Luce, James.

In: Cancer Investigation, Vol. 12, No. 1, 1994, p. 12-19.

Research output: Contribution to journalArticle

Balaban, Edward P. ; Graham, Mateel ; Perkins, Steve ; Sheehan, Richard G. ; Frenkel, Eugene P. ; Ross, Michael ; Bull, Joan ; Pruitt, Brian ; Periman, Phillip ; Ruud, Chris ; Luce, James. / Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma : Report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. In: Cancer Investigation. 1994 ; Vol. 12, No. 1. pp. 12-19.
@article{f03c4f5186574949817596b088003a82,
title = "Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: Report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review",
abstract = "5-Fluorouracil (5-FU) modulation with either folinic acid (FA) or methotrexate (MTX) has improved 5-FU's potential cytoreductivity. We combined MTX and FA with 5-FU to further augment 5-FU's cytoreductivity. Patients (n = 34) with advanced colorectal carcinoma were first given intravenous MTX (escalated from 30 mg/m2 to 70 mg/m2). FA (100 mg/m2) was infused 17-24 hr later, followed by 5-FU (600 mg/m2). Oral rescue doses of FA were begun 24 hr after MTX. Patients were treated every 2 weeks. No previously treated patient (n = 6) responded. Eight of the remaining 28 (29{\%} (95{\%} confidence interval, 15-47{\%} patients achieved a PR. Median survival was 9.3 months. Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29{\%} These results, in addition to a literature review, reveal that the manipulation of 5-FU by two modulating agents does not improve the response rate seen with single-agent modulation.",
author = "Balaban, {Edward P.} and Mateel Graham and Steve Perkins and Sheehan, {Richard G.} and Frenkel, {Eugene P.} and Michael Ross and Joan Bull and Brian Pruitt and Phillip Periman and Chris Ruud and James Luce",
year = "1994",
doi = "10.3109/07357909409021388",
language = "English (US)",
volume = "12",
pages = "12--19",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma

T2 - Report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review

AU - Balaban, Edward P.

AU - Graham, Mateel

AU - Perkins, Steve

AU - Sheehan, Richard G.

AU - Frenkel, Eugene P.

AU - Ross, Michael

AU - Bull, Joan

AU - Pruitt, Brian

AU - Periman, Phillip

AU - Ruud, Chris

AU - Luce, James

PY - 1994

Y1 - 1994

N2 - 5-Fluorouracil (5-FU) modulation with either folinic acid (FA) or methotrexate (MTX) has improved 5-FU's potential cytoreductivity. We combined MTX and FA with 5-FU to further augment 5-FU's cytoreductivity. Patients (n = 34) with advanced colorectal carcinoma were first given intravenous MTX (escalated from 30 mg/m2 to 70 mg/m2). FA (100 mg/m2) was infused 17-24 hr later, followed by 5-FU (600 mg/m2). Oral rescue doses of FA were begun 24 hr after MTX. Patients were treated every 2 weeks. No previously treated patient (n = 6) responded. Eight of the remaining 28 (29% (95% confidence interval, 15-47% patients achieved a PR. Median survival was 9.3 months. Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29% These results, in addition to a literature review, reveal that the manipulation of 5-FU by two modulating agents does not improve the response rate seen with single-agent modulation.

AB - 5-Fluorouracil (5-FU) modulation with either folinic acid (FA) or methotrexate (MTX) has improved 5-FU's potential cytoreductivity. We combined MTX and FA with 5-FU to further augment 5-FU's cytoreductivity. Patients (n = 34) with advanced colorectal carcinoma were first given intravenous MTX (escalated from 30 mg/m2 to 70 mg/m2). FA (100 mg/m2) was infused 17-24 hr later, followed by 5-FU (600 mg/m2). Oral rescue doses of FA were begun 24 hr after MTX. Patients were treated every 2 weeks. No previously treated patient (n = 6) responded. Eight of the remaining 28 (29% (95% confidence interval, 15-47% patients achieved a PR. Median survival was 9.3 months. Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29% These results, in addition to a literature review, reveal that the manipulation of 5-FU by two modulating agents does not improve the response rate seen with single-agent modulation.

UR - http://www.scopus.com/inward/record.url?scp=0028032171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028032171&partnerID=8YFLogxK

U2 - 10.3109/07357909409021388

DO - 10.3109/07357909409021388

M3 - Article

C2 - 8281461

AN - SCOPUS:0028032171

VL - 12

SP - 12

EP - 19

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 1

ER -